Ridgetech is no longer a drugstore chain. After selling the retail network and buying an online wholesaler in late winter of the prior fiscal year, the Hangzhou company is a China pharmaceutical distributor whose latest annual print, for the year ended March 31, 2026, shows that the pivot grew the top line while still leaving continuing operations in the red. The investment debate is whether Allright, the acquired digital platform, can turn a thin-margin Zhejiang wholesaler into a scalable franchise, or whether the Nasdaq listing is mainly a wrapper for repeated equity issuance around a business that still depends on the very retail chain it just sold.
The operating tension sits in the mix. Offline wholesale still produced about $118 million of the $132 million year. Online platform sales reached $14 million only because Allright sat in the prior year for a single month. Blended gross margin stayed near 4 percent while the online slice compressed as platform fees filled a full year of selling costs. The mix shift is real, but it has not yet paid for the cost of running two engines. Year-end cash looks ample next to the listing, yet operating cash turned negative as receivables rose.
The capital-markets overlay is louder than the operating print. A reverse share split in early April reset the count, after which an at-the-market program lifted ordinary shares into the low millions by mid-July. The chairman separately took preferred stock carrying one hundred votes per share, enough to dominate any ordinary-share vote. The question the next several prints resolve is whether Allright mix and customer diversification can lift cash earnings enough that the listing stops needing the printer.